📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease (2021)

First Author: Wellens J

Attributed to: A UK underpinning platform to study immunology and immunopathology of COVID-19:The UK Coronavirus Immunology Consortium funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.10.13.21264916

Publication URI: http://dx.doi.org/10.1101/2021.10.13.21264916

Type: Preprint